Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cediranib + olaparib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cediranib + olaparib is a combination of two small molecule drugs investigated primarily for the treatment of various cancers, including ovarian, fallopian tube, peritoneal, and metastatic pancreatic ductal adenocarcinoma. Cediranib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that disrupts tumor angiogenesis by inhibiting blood vessel formation. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that impairs DNA damage repair in cancer cells with homologous recombination repair deficiencies. The combination aims to enhance anti-tumor efficacy by simultaneously targeting tumor vasculature and DNA repair pathways[1][3][5][6]. Clinical studies have shown improved progression-free survival in some settings but limited activity in others.
- Brand names
- Lynparza
- Other names
- cediranib and olaparibcediranib/olaparib
02
Targets
PARP3 (Poly(adp-ribose) polymerase 3)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on cediranib + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cediranib + olaparib.